| Trial ID: | L5480 |
| Source ID: | NCT01332370
|
| Associated Drug: |
Rosiglitazone + Metformin
|
| Title: |
Prescription Patterns, Resource Utilization & Costs - Add-on Therapy With Anti Dipeptidyl Peptidase-IVs vs Rosiglitazone
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Rosiglitazone + Metformin|DRUG: Sitagliptin + Metformin
|
| Outcome Measures: |
Primary: medical resource utilization, Direct healthcare and indirect sick leave costs, at least 12 months following first prescription with RSG or STG as an add-on therapy to MET monotherapy. |
|
| Sponsor/Collaborators: |
Sponsor: GlaxoSmithKline
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
5391
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2009-12
|
| Completion Date: |
2010-12
|
| Results First Posted: |
|
| Last Update Posted: |
2017-06-02
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT01332370
|
